Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025

Largest global clinical trial in pediatric myopia met primary efficacy endpoint of proportion of patients with confirmed progression of -0.75D and key secondary endpoint of annual progression rate Treatment effects evident by month 12 and sustained through month 36; greatest treatment benefit observed in younger children, in participants with a history of myopia progression, or when administered […]